Patient Adherence – a major opportunity to increase
profit and patient wellbeing.
OVERVIEW The US health insurance industry is a key stakeholder and potential beneficiary in the
‘adherence opportunity’ – which is worth $374bn per annum. Research shows that adherence is typically
around 50% and frequently less across chronic disease categories such as respiratory, cardio and diabetes.
ADHERENCE and the patient
• Drivers for non-adherence on the patient side include emotional and
psychological factors e.g. ‘forgetfulness’
• Concern about treatment side effects from poor understanding and
awareness
• Failure to understand benefit and impact of treatment on the disease
Overall costs and impacts associated with failure are significant:
50%
Adherence
125k
$200bn
Hospitalisations
and deaths
costs
THE OPPORTUNITY
Improving adherence is therefore an imperative, a win-win for patients and for the wider network of
stakeholders including the pharma industry and most importantly the medical insurance sector. In short:
Improved
adherence =
Increased
profits
+
Brand
equity
HOW
Our research has identified a range of proprietary technologies and opportunities for the insurance and
pharma sector to target increases in adherence - leading to unique benefits. These opportunities sit within
the patient network e.g. at patient-pack interaction and extend through patient connections via intelligent
digital services delivered by smart devices, call centres and others.
If you are interested in discussing the “adherence opportunity” please let us know and we will be happy to
share more information by email and arrange a phone call to introduce our companies and research.
With thanks. Chris Waterhouse, director iDi Pac & Dr Chris Thorpe, director Intelligent Design, UK
Contact: Chris Waterhouse, direct +44 (0)1420 538055 mobile +44 (0)7752 668409